• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's Intraday Session

    12/5/22 12:31:45 PM ET
    $AMPE
    $CLVS
    $DRMA
    $ENOB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AMPE alert in real time by email

    Gainers

    • Nymox Pharmaceutical (NASDAQ:NYMX) shares increased by 32.7% to $0.38 during Monday's regular session. As of 12:30 EST, Nymox Pharmaceutical's stock is trading at a volume of 3.2 million, which is 4414.3% of its average full-day volume over the last 100 days. The company's market cap stands at $34.3 million.
    • SCWorx (NASDAQ:WORX) shares moved upwards by 28.95% to $0.72. As of 12:30 EST, SCWorx's stock is trading at a volume of 202.1K, which is 441.6% of its average full-day volume over the last 100 days. The company's market cap stands at $9.4 million.
    • Shuttle Pharmaceuticals (NASDAQ:SHPH) shares rose 24.87% to $3.01. The current volume of 22.2 million shares is 899.0% of Shuttle Pharmaceuticals's average full-day volume over the last 100 days (last updated at 12:30 EST). The company's market cap stands at $40.7 million.
    • Vivani Medical (NASDAQ:VANI) stock rose 24.53% to $1.72. As of 12:30 EST, this security is trading at a volume of 242.3K shares, making up 419.5% of its average full-day volume over the last 100 days. The company's market cap stands at $87.1 million.
    • Yumanity Therapeutics (NASDAQ:YMTX) stock rose 20.93% to $2.08. Trading volume for this security as of 12:30 EST is 1.3 million, which is 4022.8% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $22.5 million.
    • Iovance Biotherapeutics (NASDAQ:IOVA) shares moved upwards by 20.39% to $8.23. Trading volume for this security as of 12:30 EST is 11.8 million, which is 406.3% of its average full-day volume over the last 100 days. The company's market cap stands at $1.2 billion.

    Losers

    • Dermata Therapeutics (NASDAQ:DRMA) shares declined by 59.8% to $0.26 during Monday's regular session. The current volume of 4.9 million shares is 2582.3% of Dermata Therapeutics's average full-day volume over the last 100 days (last updated at 12:30 EST). The market value of their outstanding shares is at $3.1 million.
    • Meihua Intl Medical Techs (NASDAQ:MHUA) shares decreased by 26.29% to $9.79. Meihua Intl Medical Techs's stock is trading at a volume of 51.7K shares as of 12:30 EST. This is 204.0% of its average full-day volume over the last 100 days. The company's market cap stands at $234.3 million.
    • Ampio Pharmaceuticals (AMEX:AMPE) shares declined by 17.05% to $0.29. Trading volume for this security as of 12:30 EST is 119.2K, which is 28.4% of its average full-day volume over the last 100 days. The company's market cap stands at $4.3 million.
    • Gelesis Holdings (NYSE:GLS) shares decreased by 16.65% to $0.4. The market value of their outstanding shares is at $29.2 million.
    • Enochian BioSciences (NASDAQ:ENOB) shares declined by 15.13% to $1.01. Trading volume for this security as of 12:30 EST is 87.9K, which is 175.5% of its average full-day volume over the last 100 days. The company's market cap stands at $53.4 million.
    • Clovis Oncology (NASDAQ:CLVS) stock declined by 12.72% to $0.3. Trading volume for Clovis Oncology's stock is 2.2 million as of 12:30 EST. This is 55.9% of its average full-day volume over the last 100 days. The company's market cap stands at $43.5 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AMPE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AMPE
    $CLVS
    $DRMA
    $ENOB

    CompanyDatePrice TargetRatingAnalyst
    Iovance Biotherapeutics Inc.
    $IOVA
    2/25/2026$5.00Mkt Perform → Mkt Outperform
    Citizens
    Iovance Biotherapeutics Inc.
    $IOVA
    7/15/2025$1.00Neutral → Sell
    Goldman
    Iovance Biotherapeutics Inc.
    $IOVA
    5/16/2025$2.00Buy → Neutral
    UBS
    Iovance Biotherapeutics Inc.
    $IOVA
    5/12/2025Buy → Hold
    Truist
    Iovance Biotherapeutics Inc.
    $IOVA
    5/9/2025Mkt Outperform → Mkt Perform
    Citizens JMP
    Iovance Biotherapeutics Inc.
    $IOVA
    10/24/2024$17.00Buy
    UBS
    Iovance Biotherapeutics Inc.
    $IOVA
    7/29/2024$19.00 → $10.00Overweight → Neutral
    Piper Sandler
    Iovance Biotherapeutics Inc.
    $IOVA
    11/20/2023$12.00Buy
    Goldman
    More analyst ratings

    $AMPE
    $CLVS
    $DRMA
    $ENOB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Financial Officer Roche Corleen M.

    4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)

    3/11/26 5:25:27 PM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Iovance Biotherapeutics Inc.

    4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)

    3/11/26 5:04:33 PM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Iovance Biotherapeutics Inc.

    4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)

    3/11/26 5:01:07 PM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AMPE
    $CLVS
    $DRMA
    $ENOB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Iovance Biotherapeutics upgraded by Citizens with a new price target

    Citizens upgraded Iovance Biotherapeutics from Mkt Perform to Mkt Outperform and set a new price target of $5.00

    2/25/26 7:38:09 AM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Iovance Biotherapeutics downgraded by Goldman with a new price target

    Goldman downgraded Iovance Biotherapeutics from Neutral to Sell and set a new price target of $1.00

    7/15/25 8:37:18 AM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Iovance Biotherapeutics downgraded by UBS with a new price target

    UBS downgraded Iovance Biotherapeutics from Buy to Neutral and set a new price target of $2.00

    5/16/25 8:01:50 AM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AMPE
    $CLVS
    $DRMA
    $ENOB
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    February 16, 2024 - FDA Approves First Cellular Therapy to Treat Patients with Unresectable or Metastatic Melanoma

    For Immediate Release: February 16, 2024 Today, the U.S. Food and Drug Administration approved Amtagvi, the first cellular therapy indicated for the treatment of adult patients with a type of skin cancer (melanoma) that is unable to be removed with surgery (unresectable) or has spread to other parts of the body (metastatic) that previously has been treated with other therapies (a PD-1 blocking antibody, and if B

    2/16/24 3:48:47 PM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for RUBRACA issued to CLOVIS ONCOLOGY INC

    Submission status for CLOVIS ONCOLOGY INC's drug RUBRACA (SUPPL-13) with active ingredient RUCAPARIB CAMSYLATE has changed to 'Approval' on 12/21/2022. Application Category: NDA, Application Number: 209115, Application Classification: Efficacy

    12/22/22 4:37:40 AM ET
    $CLVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for RUBRACA issued to CLOVIS ONCOLOGY INC

    Submission status for CLOVIS ONCOLOGY INC's drug RUBRACA (SUPPL-11) with active ingredient RUCAPARIB CAMSYLATE has changed to 'Approval' on 06/10/2022. Application Category: NDA, Application Number: 209115, Application Classification: Efficacy

    6/13/22 2:20:18 PM ET
    $CLVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMPE
    $CLVS
    $DRMA
    $ENOB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $AMPE
    $CLVS
    $DRMA
    $ENOB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $AMPE
    $CLVS
    $DRMA
    $ENOB
    SEC Filings

    View All

    Next-Generation Cancer Therapies Post Breakthrough Results Across Multiple Tumor Types

    Issued on behalf of Oncolytics Biotech Inc.VANCOUVER, BC, March 5, 2026 /CNW/ -- Equity-Insider.com News Commentary -- The five-year cancer survival rate in the United States has reached a record 70%, reflecting decades of progress in early detection, targeted therapy, and immunotherapy[1]. Yet cancer remains the second-leading cause of death worldwide, with an estimated 2.1 million new diagnoses expected in 2026 alone and mortality rates still climbing among younger populations[2]. Companies delivering next-generation oncology treatments across multiple tumor types include Oncolytics Biotech (NASDAQ:ONCY), Vir Biotechnology (NASDAQ:VIR), Iovance Biotherapeutics (NASDAQ:IOVA), C4 Therapeutic

    3/5/26 9:00:00 AM ET
    $CCCC
    $IMCR
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    SCWorx Announces New SaaS and Data Management Customer Supporting a Prominent Southeastern Healthcare Provider's Workday Platform

    New York, NY, March 04, 2026 (GLOBE NEWSWIRE) -- SCWorx Corp. (NASDAQ:SCWX), a leading provider of data management, analytics, and interoperability solutions for healthcare organizations, today announced that it has signed a new SaaS and data management customer agreement with a prominent Southeastern healthcare provider in support of its implementation and ongoing optimization of its Workday platform. The health system's integrated delivery network (IDN) comprises over 700 beds across multiple acute care hospitals and outpatient facilities, serving communities throughout the region. Under the agreement, SCWorx will provide its cloud-based data management and governance solutions to suppo

    3/4/26 10:11:22 AM ET
    $SCWX
    $WORX
    Computer Software: Prepackaged Software
    Technology
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    Iovance Biotherapeutics to Present at Upcoming Conferences

    SAN CARLOS, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the following upcoming conferences: TD Cowen 46th Annual Healthcare Conference Presentation: March 2, 2026 at 9:50 a.m. ETBoston, MA Barclays 28th Annual Global Healthcare ConferenceFireside Chat: March 11, 2026 at 9:30 a.m. ETMiami, FL The live and archived webcasts will be available at https://ir.iovance.com/news-events/events-presentations. About Iovance Biotherapeuti

    2/26/26 8:00:00 AM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Commercial Officer Kirby Daniel Gordon bought $55,200 worth of shares (30,000 units at $1.84) (SEC Form 4)

    4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)

    6/6/25 4:05:31 PM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Regulatory Officer Puri Raj K. bought $9,743 worth of shares (5,600 units at $1.74), increasing direct ownership by 3% to 206,852 units (SEC Form 4)

    4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)

    5/27/25 4:06:43 PM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Interim CEO & General Counsel Vogt Frederick G bought $42,250 worth of shares (25,000 units at $1.69), increasing direct ownership by 7% to 374,646 units (SEC Form 4)

    4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)

    5/16/25 4:05:18 PM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Dermata Therapeutics Inc. filed SEC Form 8-K: Leadership Update

    8-K - Dermata Therapeutics, Inc. (0001853816) (Filer)

    2/25/26 4:05:32 PM ET
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Iovance Biotherapeutics Inc.

    10-K - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Filer)

    2/24/26 9:35:04 AM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Iovance Biotherapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

    8-K - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Filer)

    2/24/26 8:00:40 AM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AMPE
    $CLVS
    $DRMA
    $ENOB
    Leadership Updates

    Live Leadership Updates

    View All

    SCWorx Corp. Appoints New Chief Technology Officer to Accelerate Innovation in Healthcare Data Solutions

    Tampa, FL, Sept. 03, 2025 (GLOBE NEWSWIRE) -- SCWorx Corp. (NASDAQ:WORX), a leading provider of data management and software solutions for the healthcare industry, today announced the appointment of Anders Ohlsson, a seasoned technology executive, as its new Chief Technology Officer (CTO). This strategic hire underscores SCWorx's commitment to advancing its data platform and expanding its suite of data management and software solutions for healthcare providers. Mr. Ohlsson has over 25 years of experience in software engineering, cloud infrastructure, and machine learning applications. Prior to joining SCWorx, he held senior leadership roles at WideOrbit, where he spearheaded the developm

    9/3/25 11:44:49 AM ET
    $WORX
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    Iovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer

    SAN CARLOS, Calif., July 15, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced the appointment of Corleen Roche as Chief Financial Officer (CFO), effective August 6th, 2025. "I am pleased to welcome Corleen to Iovance at such an important stage in our first commercial launch," said Frederick G. Vogt, Ph.D., J.D., Interim Chief Executive Officer, President and General Counsel. "Corleen's experience in executive financial leadership roles and multiple product launches will be in

    7/15/25 7:30:49 AM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Iovance Biotherapeutics Appoints Marc R. Theoret, M.D. as Senior Vice President, Regulatory Strategy

    SAN CARLOS, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced the appointment of Marc. R Theoret, M.D. to assume the newly created position of Senior Vice President, Regulatory Strategy, where he will focus on clinical regulatory strategy for Iovance's pipeline. Effective immediately, Dr. Theoret will report to Dr. Raj K. Puri, M.D., Ph.D., Chief Regulatory Officer. For more than 15 years, Dr. Theoret held various roles in the United States Food and Drug Administrat

    7/10/25 4:01:00 PM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AMPE
    $CLVS
    $DRMA
    $ENOB
    Financials

    Live finance-specific insights

    View All

    Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Updates on Tuesday, February 24, 2026

    SAN CARLOS, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will host a conference call and live audio webcast on Tuesday, February 24, 2026 at 8:30 a.m. ET to report its fourth quarter and full year 2025 financial results and corporate updates. To listen to the live or archived audio webcast, please register at https://edge.media-server.com/mmc/p/5rbo34au. The live and archived webcast can be accessed in the Investors section of the Company's website, IR.Iovance.com. The archived webcast w

    2/11/26 4:05:00 PM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Iovance Biotherapeutics Highlights Business Achievements, Pipeline Milestones, and Third Quarter 2025 Results

    Quarterly Revenue Growth of 13% to ~$68 Million  Gross Margin Increased to 43% on Improved Execution and Operational Efficiency Best-in-Class Clinical Profile for Lifileucel in Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) with Median Duration of Response Not Reached after 25+ Months Follow Up SAN CARLOS, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today reported third quarter and year-to-date 2025 financial results, business achievements, pipeline progress

    11/6/25 8:00:00 AM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Iovance Biotherapeutics to Host Third Quarter 2025 Financial Results and Corporate Updates Webcast on Thursday, November 6, 2025

    SAN CARLOS, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its third quarter 2025 financial results and corporate updates before market on Thursday, November 6, 2025. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update on November 6, 2025, at 8:30 a.m. ET. To listen to the live or archived audio webcast, please register at https://edge.media-server.com/mmc/p/pg9qgz86. The live and archived webcast can be accessed

    10/23/25 4:05:00 PM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AMPE
    $CLVS
    $DRMA
    $ENOB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by SCWorx Corp.

    SC 13G - SCWorx Corp. (0001674227) (Subject)

    12/5/24 7:17:43 AM ET
    $WORX
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    SEC Form SC 13G filed by SCWorx Corp.

    SC 13G - SCWorx Corp. (0001674227) (Subject)

    11/26/24 5:02:01 PM ET
    $WORX
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    SEC Form SC 13G filed by Meihua International Medical Technologies Co. Ltd.

    SC 13G - Meihua International Medical Technologies Co., Ltd. (0001835615) (Subject)

    11/14/24 6:08:55 PM ET
    $MHUA
    Medical/Dental Instruments
    Health Care